TrovaGene, Inc. (NASDAQ:TROV) will be announcing its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.

TrovaGene, Inc. (TROV) opened at 0.96 on Wednesday. The stock’s 50 day moving average is $1.07 and its 200 day moving average is $1.34. TrovaGene, Inc. has a 52 week low of $0.61 and a 52 week high of $5.98. The company’s market capitalization is $29.73 million.

Separately, Maxim Group raised shares of TrovaGene from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research note on Wednesday, April 12th.

TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with's FREE daily email newsletter.